WARSZAWSKI UNIWERSYTET MEDYCZNY

Their core work

The Medical University of Warsaw is Poland's leading medical university, contributing clinical expertise in specialized surgical and medical fields to European research consortia. Their H2020 work spans immuno-oncology, complex vascular surgery (specifically aortic aneurysm repair and spinal cord protection), rare diseases, and reproductive medicine. They bring clinical trial capability and translational research capacity — bridging lab findings to patient care — particularly in areas where surgical precision and molecular biology intersect.

What they specialise in

How they've shifted over time

Early H2020 involvement (2016-2018) centered on cancer research and complex surgical interventions — immuno-oncology strategy-building and aortic surgery clinical trials. From 2019 onward, the focus shifted toward rare diseases, data sharing (FAIR principles), and molecular reproductive medicine including endometriosis. The trajectory shows a move from broad oncology and surgical excellence toward more specialized molecular medicine and patient-centered research frameworks.

Moving toward molecular-level disease research (microRNA, omics, stem cells) with growing emphasis on rare and underserved conditions — a good fit for consortia targeting precision medicine or unmet medical needs.

How they like to work

MUW primarily joins consortia as a participant (3 of 4 projects), contributing clinical expertise to large international teams — their 187 unique partners across 37 countries reflect broad but not deep engagement. They coordinated one project (STREAM), demonstrating leadership capability in their core strength of immuno-oncology. Their consortium sizes suggest comfort in large multi-partner frameworks rather than small focused teams.

An extensive network of 187 unique partners across 37 countries, largely built through participation in large-scale European programmes like EJP RD. Their geographic reach is truly pan-European with global elements, though the network breadth comes more from joining large consortia than from repeated bilateral partnerships.

What sets them apart

MUW combines clinical hospital infrastructure with academic research in a way that few Polish institutions can match at this scale — they are a medical university with direct access to patients and surgical theatres. Their niche in aortic surgery spinal cord protection (PAPA-ARTIS) is exceptionally specialized, and their transition into molecular reproductive medicine gives them a distinctive profile. For consortium builders, they offer a Central European clinical partner with real translational capacity — bench to bedside — in a country with competitive research costs.

Highlights from their portfolio

• STREAM
  Their only coordinated project and largest by far (EUR 640K), focused on building immuno-oncology excellence through international cooperation — shows leadership ambition in cancer research.
• PAPA-ARTIS
  A highly specialized randomized controlled trial on preventing paraplegia during aortic aneurysm repair — one of the most technically demanding surgical research areas in Europe.
• TRENDO
  Their most recent project signals a new research direction into endometriosis using microRNA and stem cell approaches — molecular reproductive medicine is an underserved field with growing EU attention.